Krishna Abhishek, Jayachandran Mamatha, Sacheendran Dhanya, George Thomas, Palatty Princy Louis, Baliga Manjeshwar Shrinath
Department of Radiation Oncology, Mysore Medical College and Research Institute, Irwin Road, Mysuru, Karnataka India.
Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala 682041 India.
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):1782-1791. doi: 10.1007/s12070-023-03753-x. Epub 2023 Apr 8.
According to recent studies, head and neck cancers (HNC) make up a substantial proportion of all cancers in India and are proportionately high in the lower socioeconomic people practising tobacco and alcohol. Chemotherapy is a crucial component of treating HNC, and this study was carried out to determine the Cost Minimization Analysis (CMA) by comparing the price of the high and least expensive branded drugs marketed in India. This study was performed to understand the cost difference (CD), Cost ratio (CR) and percentage of cost variation (PCV) of both individual drugs and the standard anticancer regimens. The Current Index of Medical Stores was used to determine the costs of the most and least expensive branded medications and analysed. The results indicated that Paclitaxel-Cisplatin-5 Fluoruracil chemotherapy regimen exhibited the greatest variance in cost, with the Jan Aushadhi brand of medicine costing 8.1 times and 4.3 times less than the most expensive and cheapest branded drugs, respectively. The cost of the concurrent cisplatin regimen with Jan Aushadi Medicine was Rs 1764, Rs 3489.64 with the lowest branded drug, and Rs 8477 with the most expensive branded drug. Also when compared to Jan Aushadhi medication, the cost of Ciplatin was 4.8 times higher with the most expensive branded drug and 2 times higher with the least expensive branded drug. As far as the authors are aware of this is the first study that addresses the pharmacoeconomic appraisal of treating HNC with various chemotherapy and chemoirradiation regimens. This study will help oncologists, pharmacists, and healthcare workers comprehend the financial advantages of treating breast cancer with less expensive chemotherapeutic agents instead of brand-name medications.
根据最近的研究，头颈癌（HNC）在印度所有癌症中占相当大的比例，在社会经济地位较低、有烟草和酒精使用习惯的人群中比例更高。化疗是治疗头颈癌的关键组成部分，本研究旨在通过比较印度市场上高价和最便宜品牌药物的价格来进行成本最小化分析（CMA）。本研究旨在了解个体药物和标准抗癌方案的成本差异（CD）、成本比率（CR）和成本变化百分比（PCV）。使用当前药店指数来确定最昂贵和最便宜品牌药物的成本并进行分析。结果表明，紫杉醇-顺铂-5-氟尿嘧啶化疗方案的成本差异最大，简·奥沙迪（Jan Aushadhi）品牌药物的成本分别比最昂贵和最便宜品牌药物低8.1倍和4.3倍。使用简·奥沙迪药物的顺铂联合方案成本为1764卢比，最便宜品牌药物的成本为3489.64卢比，最昂贵品牌药物的成本为8477卢比。此外，与简·奥沙迪药物相比，最昂贵品牌药物的顺铂成本高4.8倍，最便宜品牌药物的顺铂成本高2倍。据作者所知,这是第一项针对各种化疗和放化疗方案治疗头颈癌的药物经济学评估的研究。本研究将帮助肿瘤学家、药剂师和医护人员理解使用较便宜的化疗药物而非名牌药物治疗乳腺癌的经济优势。
